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Abstract
Background: The research objectives of the 5-year and 10-year assessments in the Finnish degenerative meniscal
lesion study (FIDELITY) are twofold: (1) to assess the long-term efficacy of arthroscopic partial meniscectomy (APM)
in adults (age 35 to 65 years) with a degenerative meniscus tear and (2) to determine the respective effects of APM
and degenerative meniscus tear on the development of radiographic and clinical knee osteoarthritis (OA).
Methods and design: FIDELITY is an ongoing multi-center, randomized, participant and outcome assessor blinded,
placebo-surgery-controlled trial in 146 patients. This statistical analysis plan (SAP) article describes the overall
principles for analysis of long-term outcomes (5-year and 10-year follow up), including how participants will be
included in each analysis, the primary and secondary outcomes and their respective analyses, adjustments for
covariates, and the presentation of the results. In addition, we will present the planned sensitivity and subgroup
analyses.
Discussion: To assess the long-term efficacy of APM on knee symptoms and function we are carrying out a long-
term (5-year and 10-year) follow up of our placebo-surgery-controlled FIDELITY trial according to statistical
principles outlined in detail in this document. As our second primary objective, whether APM (resection of torn
meniscus tear) accelerates or delays the development of knee osteoarthritis in patients with an arthroscopically
verified degenerative tear of the medial meniscus, a pre-registered follow-up is also carried out.
Trial registration: ClinicalTrials.gov, NCT00549172 (Arthroscopy in the Treatment of Degenerative Medial Meniscus
Tear). Registered on 25 October 2007 (NCT00549172). ClinicalTrials.gov, NCT01052233 (Development of Knee
Osteoarthritis After Arthroscopic Partial Resection of Degenerative Meniscus Tear). Registered on 20 January 2010.
Keywords: Statistical analysis plan, Randomized controlled trial, Arthroscopic partial meniscectomy, Osteoarthritis
Introduction
Trial overview and purpose of the statistical analysis plan
The Finnish degenerative meniscal lesion study (FIDEL-
ITY) is a trial to assess the efficacy of arthroscopic
partial meniscectomy (APM) in patients with a degen-
erative meniscus tear. The primary outcome assessment
point of the trial was at 1 year post surgery. The original
study protocol [1] and the results of 1-year and 2-year
analyses [2, 3] and a secondary analysis focusing on
mechanical symptoms [4] are published.
To safeguard against the imminent risk of outcome
reporting bias, selective reporting, and data-driven inter-
pretation of results, this statistical analysis plan (SAP,
Version 2.0) for the 5-year and 10-year follow up is pub-
lished as an update to the previously published protocol
[1]. The original study protocol [1] provides more details
on the trial rationale, eligibility criteria, interventions,
data management, and methods for limiting bias. This
SAP follows the guidelines for writing SAPs provided by
Gamble et al. [5] and describes the overall principles for
analysis of long-term outcomes (5-year and 10-year
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follow up), including how participants will be included
in each analysis, the primary and secondary outcomes
and their respective analyses, adjustments for covariates,
and the presentation of the results. In addition, we will
present the planned sensitivity and subgroup analyses.
The trial results will be reported according to the Con-
solidated standards of reporting trials (CONSORT)
guidelines for randomized controlled trials (RCTs) [6].
Background
By the end of the 21st century, APM had become the
most common orthopedic procedure with well over half
a million such surgeries performed annually in the USA
alone [7, 8], mostly in middle-aged and older patients
[8]. According to conventional wisdom, APM was
thought to result in short-term improvement in knee
function and quality of life. However, a series of rigorous
trials, summarized in three recent systematic reviews
and meta-analyses, provide compelling evidence that
APM offers little short-term to medium-term benefit
above sham surgery or non-surgical management in
most patients with knee pain and degenerative meniscus
tear [9, 10]. Recent evidence thus convincingly contra-
dicts the widely held contention that APM is beneficial
in improving knee symptoms or function, but there is
still uncertainty about the possible undesirable conse-
quences of the procedure [11]. Overall, the risk of ad-
verse events within 90 days of the procedure appears
low, but serious adverse events (including pulmonary
embolism and infection) have been associated with this
surgery [12, 13].
However, there is mounting evidence to suggest that
APM is associated with increased risk of accelerated
progression of knee osteoarthritis (OA) and earlier need
for “corrective” surgery (high tibial osteotomy (HTO) or
total knee replacement (TKR)) in middle-aged to older
patients [14, 15]. It still remains unclear whether the in-
creased risk is due to the meniscus tear per se, the surgi-
cal procedure (APM), or if there is an interaction
between the two. This question cannot be addressed
simply by evaluating the outcome of patients who have
undergone APM, because the role of the underlying de-
generative process and the surgical procedure cannot be
disentangled in such a design [16]. Given the current
uncertainty about the potential effect of APM on the de-
velopment or progression of knee OA, we are planning
to address this particular issue by carrying out an ad-
junct, pre-registered analysis of the FIDELITY trial at 5
and 10 years after randomization. The biological ra-
tionale behind these studies is that resection of the
torn meniscus (APM) has an effect on the progres-
sion of degenerative knee disease: some argue that
APM cures symptoms and slows down the develop-
ment of OA while others assert the contrary.
Objectives
The following two research questions capture the pri-
mary objectives of these 5-year and 10-year follow-up
investigations:
1. What is the long-term efficacy of APM (versus
placebo surgery) on functional outcome and knee
symptoms in patients with an arthroscopically
verified degenerative tear of the medial meniscus?
2. Does APM either accelerate or delay the
development/progression of radiographic and
clinical knee OA in these patients?
Trial design
FIDELITY is a multicenter, randomized, participant and
outcome assessor blinded, placebo-surgery-controlled trial.
This study is carried out at five orthopedic clinics of
Tampere University Hospital Hatanpää, Kuopio University
Hospital, Helsinki Central Hospital (Jorvi), Turku Univer-
sity Hospital, and the Central Finland Central Hospital in
Jyväskylä, all in Finland. The study group at each center
consists of a main investigator (an orthopedic surgeon
experienced in knee arthroscopy) who took care of the
recruitment of the patients and all surgical procedures, a
study nurse, an orthopedic surgeon for possible postopera-
tive problems and another for scheduled follow-up exami-
nations, the latter two both blinded to the treatment
allocation. Patients were enrolled between 2007 and 2012
and all follow-up assessments were carried out between
October 2013 and January 2017. The study was approved
by the Pirkanmaa Hospital District’s committee of ethics
(no. R06157). The two research questions were registered
as separate studies in the ClinicalTrials database (Clinical
trials.gov identifiers NCT00549172 and NCT01052233).
The study process shown in Fig. 1 provides a brief outline
of the trial. The eligibility criteria for the study are pre-
sented in Box 1.
Methods
Outcomes
Objective 1: efficacy of arthroscopic partial meniscectomy
(NCT00549172)
To assess the efficacy of APM (versus placebo surgery)
on the functional outcome and knee symptoms in pa-
tients with an arthroscopically verified degenerative tear
of the medial meniscus, we will be using the same three
patient-relevant outcomes (PROMs) that were used as
our primary outcomes in the previous, 1-year and 2-year
follow-up publications of this data [2, 3].
The primary outcomes are:
1. Western Ontario Meniscal Evaluation Tool
(WOMET) score, a disease-specific instrument for
assessing quality of life that was developed and
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validated for patients with meniscal pathologic
conditions [17, 18]
2. Lysholm knee score, the most commonly used
outcome instrument for various knee conditions
[19, 20] and a tool that has also been validated for
patients with meniscal injury [21]
3. Knee pain after exercise, assessed on an 11-point
scale ranging from 0 (no pain) to 10 (extreme pain)
The secondary outcome is the frequency of unblinding
in the two study groups: patients with inadequate relief
of symptoms underwent unblinding of the treatment-
group allocation.
These outcomes and the justification for these have
previously been elaborated in detail [1–4].
Objective 2: development of knee OA (NCT01052233)
To assess whether APM either accelerates or delays the
development/progression of radiographic and clinical
knee OA in these patients, we will use radiographs and
established clinical criteria to assess the progression of
knee OA at the 5-year and 10-year time point after the
index surgeries as follows.
The primary outcomes are:
1. Development/progression of radiographic OA
a. An increase of one grade or more in the
Kellgren-Lawrence (KL) knee OA grading
(dichotomous outcome: yes or no)
b. The KL scale is a semi-quantitative instrument
(ordered categorical grades 0–4) to assess the
severity of radiographic tibiofemoral knee OA
[22]. Patients who have undergone an
osteotomy or a total knee replacement during
follow up will be considered to have progressed
radiographically according to the definition above.
2. Radiographic progression based on the sum of
marginal tibiofemoral osteophyte grades and
tibiofemoral joint space narrowing (JSN) grades
(Osteoarthritis Research Society International
(OARSI)) atlas (continuous outcome,
hypothetical range 0–18)
Fig. 1 An outline of the study process of the FIDELITY trial
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The OARSI atlas is a semi-quantitative instrument (or-
dered categorical grade 0–3) with focus to assess the sever-
ity of JSN and osteophytes, respectively, in knee OA [23].
The secondary outcome:
1. Knee OA according to the American College of
Rheumatology Clinical Criteria [24]
Auxiliary outcomes:
2. Development/progression of radiographic OA by a
grade increase of 0.5 or more in the Kellgren-
Lawrence (KL) knee OA grading (dichotomous
outcome: yes or no)
a. More sensitive than a one full grade (above) but
may potentially capture “too many” patients as
progressed in the two treatment arms, in
particular at the 10-year follow up
3. Quantitative analysis of the joint-space width based
on radiographs
4. Time-to-event analysis (OA-related surgery,
arthroplasties or osteotomies)
5. Magnetic resonance imaging (MRI)-based progression
by semi-quantitative scoring (MOAKS) [25]
6. MRI-based progression of knee degeneration by
quantitative assessment of change in OA features
(cartilage, bone, bone marrow lesions, synovitis, and
meniscus integrity and extrusion)
7. Lower extremity alignment (mechanical axis):
change from baseline to 5 years
8. Patient satisfaction and self-rated improvement
9. Patients’ return to normal activities
10. The presence of mechanical symptoms [4]
11. Clinical knee examination
12. Serious adverse events
13. Frequency of repeat APM, and the number of
osteotomies and knee arthroplasties
14. Possible derivates from the above noted outcomes
For all radiographic outcomes, two experienced muscu-
loskeletal radiologist (JK, NS), unaware of the treatment
allocation and clinical data, will grade the baseline, and
the 5- and 10-year radiographs of the operated (index)
knee of all participants. After readings by both readers, a
consensus will be sought. All the analyses of secondary
outcomes are supportive, exploratory, and/or hypothesis-
generating.
Rationale for outcomes to be reported and for the
statistical analyses
For the assessment of the efficacy of APM (NCT00549172),
we will use the same PROMs used in the previous publica-
tions depicting the 1-year [2] and 2-year [3] follow-up find-
ings. To safeguard against potential multiplicity effects [26]
in this analysis, we will interpret the treatment effect esti-
mates and their 95% CIs for all our three primary outcomes.
As for the evaluation of the development/progression of
knee OA (NCT01052233), the 5-year follow up is the first
time point one can reasonably expect any OA-related
changes to take place or to be quantifiable. Having said
that, the outcome measures we originally registered in the
ClinicalTrials.gov database (i.e., KL grade and OA as de-
fined by the American College of Rheuatologists (ACR)
clinical criteria) are quite insensitive to change, so we have
decided to add the sum of OARSI atlas osteophyte grades
and JSN grades as an additional primary outcome of
radiographic progression of OA.
Statistical analysis
All the analyses will be performed according to the
intention to treat (ITT) principle or, if impossible, using
the full analysis set [27]. In sensitivity analysis we will also
perform per-protocol (PP) analyses. For all outcomes, 95%
Box 1 Inclusion and exclusion criteria used in the
FIDELITY trial
Inclusion criteria
Age: 35–65 years of age
Persistent (> 3 months) pain on the medial joint line of the knee
Pain provoked by palpation or compression of the joint line or a
positive McMurray sign
MRI showing signals characteristic of medial meniscus injury
Degenerative injury to the medial meniscus confirmed at arthroscopy
Exclusion criteria
Trauma-induced onset of symptoms
Locked knee (that cannot be straightened normally)
Previous surgical procedure on the affected knee
Clinical osteoarthritis (OA) of the knee (American College of
Rheumatology criteria)
Radiological OA of the knee (Kellgren-Lawrence grade > 1) at
clinical site readings
Acute (within the previous year) fracture of the affected extremity
Decreased range of motion of the knee
Instability of the knee
MRI assessment shows pathology other than degenerative knee
disease requiring treatment other than arthroscopic partial
meniscectomy (APM)
Arthroscopic examination reveals pathologic change other than
a degenerative injury to the medial meniscus requiring
intervention other than APM
MRI magnetic resonance imaging, OA osteoarthritis
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confidence intervals for the relevant between-group differ-
ences will be calculated.
Mixed model linear regression will be used to analyze
continuous outcomes related to objective 1 (efficacy of
APM). In this model the patient will be included as the
random effect and time point (6, 12, 24, 60, or 120
months), treatment arm (APM or placebo) and their
interaction, and randomization stratification factors, i.e.,
age (35–50 years or 51–65 years), sex, absence or pres-
ence of minor degenerative changes on a radiograph (KL
grade 0 or 1), and study center, will be included as fixed
effects. The model will be adjusted for baseline values of
the respective outcome variable.
Logistic regression will be used to analyze the binary
outcomes. The model will be adjusted for the baseline
randomization stratification factors (age (35–50 years or
51–65 years), sex, and absence or presence of minor de-
generative changes on a radiograph (KL grade 0 or 1).
The method of standardization will be used to obtain
the adjusted risk ratio and the adjusted risk difference
from the logistic regression model [28]. Although
randomization was also stratified by study site, we will
not adjust for site in the logistic regression analysis due
to the small number of participants in some centers and
anticipated sparse data. Sensitivity will be analyzed in-
cluding the study site as a covariate. We will use a linear
regression model adjusted for randomization stratifica-
tion variables and the baseline value of the outcome to
analyze continuous outcomes related to objective 2.
Serious adverse events will also be reported.
Study power considerations
We note that we originally powered the study to detect
a minimal clinically important difference in the efficacy
(patient-reported) outcomes - the Lysholm and
WOMET scores (differences of at least 11.5 and 15.5
points, respectively) and in the score for knee pain after
exercise (difference of at least 2.0 points) - between the
APM and placebo-surgery groups. The original sample
size calculation for the FIDELITY trial - which was
geared at assessing the (short-term) efficacy of APM on
pain and function - yielded a sample size of 70 patients
per group. At the moment, having completed the 5-year
follow up, we know that we have 96% adherence to fol-
low up (68/70 patients in the APM and 72/76 in the
placebo-surgery groups, respectively). Based on this, we
anticipate the loss to follow up to be no more than 5
additional patients per group at the end of the follow-up
period (at 10 years), thus leaving approximately 63–67
patients per group for the final analyses. These values
provide us with 80% power, based on a two-sided type 1
error rate of 5%, to detect a 20% unit difference in the
proportion of knee OA between APM and placebo-
surgery. However, we consider it important to report
estimates of the difference with a measure of uncertainty
(such as 95% confidence intervals), even if smaller differ-
ences cannot be declared as statistically significant in a
conventional way. This is due to two reasons: (1) even a
statistically non-significant difference can potentially
exclude a clinically relevant difference in one direction
(e.g., with a 95% CI of − 3% to 15% for comparison be-
tween APM and sham APM in the frequency of knee
OA at 5 years, we can exclude a clinically relevant differ-
ence favoring APM); (2) even if the results of this par-
ticular study are inconclusive, they can inform any
future meta-analysis, as we can expect the estimate to be
unbiased due to the stringent design of the study.
Blinded data interpretation
Given the widely acknowledged importance of adequate
blinding of all stakeholders in eliminating potential bias
from the findings of RCTs [29], we have decided to add
another safeguard, a procedure we coined blinded data
interpretation [30]. In brief, our trial statistician (AT)
will perform all statistical analyses using unblinded treat-
ment groups and then provides the Writing Committee
of the trial with blinded results (groups labeled group A
and group B). The Writing Committee then contem-
plates on the interpretation of the results until a consen-
sus is reached and agrees in writing on all alternative
interpretations of the findings. We record the minutes of
this meeting in a document coined statement of inter-
pretation, which will be signed by all members of the
Writing Committee. Only after a common agreement is
reached, will the data manager and the trial statistician
break the randomization code and the correct interpret-
ation be chosen. A draft manuscript will then be final-
ized. Detailed minutes of blinded-data-interpretation
meetings will be provided as a supplement to the manu-
script. As our co-Principal Investigator (PI) (RS), re-
search coordinator (PT), and trial statistician (AT) have
performed statistical analyses for the previous publica-
tions of this trial [2–4], they will abstain from taking an
active role in the blinded-data-interpretation meeting.
Ethical considerations
The study was approved by the Pirkanmaa Hospital Dis-
trict committee of ethics (no. R06157). Our application
contained a specific, 6-point ethical analysis focusing on
the methodological rationale for use of placebo surgery,
risk-benefit assessment, and informed consent (for de-
tail, see [1]).
Dissemination
The findings of this study, whether positive, negative or
neutral, will be disseminated widely through peer-
reviewed publications and conference presentations.
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Trial status
The enrollment for the study was carried out between
December 2007 and January 2012, and subsequently, the
follow-up examinations took place between December
2013 and January 2017. We have now completed the 5-
year follow-up examinations and data management and are
ready to carry out blinded data interpretation of the 5-year
data. The 10-year follow-up examinations are ongoing.
Discussion
Arthroscopic partial meniscectomy (APM) to treat per-
sistent knee pain in middle-aged and older patients is
one of the most common orthopedic surgical procedures
in use, despite mounting evidence of no or only marginal
benefits on patient-relevant outcomes. A degenerative
meniscal tear has been reported to be an independent
risk factor for progression of cartilage damage and the
subsequent development of knee OA. However, the re-
spective roles and individual contributions of meniscal
tear and APM in the progression of OA remain unclear.
Current evidence, primarily based on observational data
and unblinded randomized controlled trials, suggest that
APM increases the risk of development of knee OA, but
the studies are hampered by confounding by indication
or high rates of crossover and loss to follow up.
Our multicenter, randomized, placebo-surgery-controlled
FIDELITY trial that involves patients with an arthroscopi-
cally verified degenerative medial meniscus tear provides an
exceptionally rigorous design to address the aforementioned
questions, namely whether arthroscopic partial meniscec-
tomy is associated with an increased risk of progression of
radiographic knee OA and whether APM has any beneficial
effect on knee pain or function or other symptoms.
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